17-DMAG prevents CD40L- and CpG-induced NF-κB activity in CLL and prevents CD40L-mediated viability. (A) Western blot analysis for MCL1 in cytoplasmic cell lysate and p65 in nuclear cell lysate prepared from CLL patient cells treated with vehicle control, or 1μM 17-DMAG for 0, 4, 8, or 24 hours, followed by stimulation with 500 ng/mL CD40L for 1 hour. Blots shown are representative of 6 patient samples, and actin and BRG1 were probed as loading controls. (B) Western blot analysis for MCL1 in cytoplasmic cell lysate and p65 in nuclear cell lysate prepared from CLL patient cells treated with vehicle control, or 1μM 17-DMAG for 0, 4, 8, 16, or 24 hours, followed by stimulation with 3.2μM CpG oligodeoxynucleotides for 3 hours. Blots shown are representative of 6 patient samples, and blots are stripped and probed with actin and BRG1 as loading controls. (C) Viability by Ann/PI at 24 hours in CLL patient cells treated with vehicle control or 17-DMAG with and without 1 μg/mL CD40L.